Use FanDuel promo code to claim $250 in bonus bets by targeting Chiefs-Raiders, Lions

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-10-04 • Permanent link

Doubts are creeping into the minds of investors as the health supplement industry reels from a recent study published in the Journal of Alzheimer's Disease. The research found that individuals who took glucosamine supplements were 25% more likely to experience mild cognitive impairment. This alarming finding has sent shockwaves through the industry, with companies like Optimum Nutrition and NOW Foods facing significant scrutiny. As a result, stock prices for these companies have plummeted, with Optimum Nutrition's shares falling by 15% in the past week alone.

Fears are growing among consumers who rely on glucosamine supplements for joint health and cognitive support. Many are questioning the safety and efficacy of these products, and some are even considering alternative treatments. As a result, sales of glucosamine supplements have begun to decline, with some companies reporting a 10% drop in sales in the past quarter. This trend is likely to have far-reaching implications for the broader healthcare industry, which relies heavily on supplements and other over-the-counter medications.

Since the 1990s, the glucosamine supplement industry has grown exponentially, with sales projected to reach $1.4 billion by 2025. The market has been driven by increasing demand for natural and holistic treatments, as well as a growing awareness of the importance of joint health. However, this growth has also been fueled by a lack of regulation and oversight, with many companies making unsubstantiated claims about the benefits of their products. Experts warn that the recent study is a wake-up call for the industry, highlighting the need for more rigorous testing and transparency.

Risks are looming for companies that manufacture and market glucosamine supplements, as investors and regulators begin to demand greater accountability. In the coming months, we can expect to see increased scrutiny of the industry, including calls for stricter regulations and more stringent testing requirements. As the industry navigates this uncertain landscape, companies will need to adapt quickly to avoid losing market share and damaging their reputation. Meanwhile, consumers will need to be vigilant in their pursuit of safe and effective treatments, seeking out products that have been thoroughly tested and proven to deliver results.